Retatrutide Half Life

TL;DR

- The retatrutide half life is reported as approximately 6 days in published clinical research, which is what makes once-weekly subcutaneous dosing workable (Jastreboff et al., 2023; Coskun et al., 2022). - This roughly 6-day value is dose proportional, meaning it holds steady across the doses studied rather than shifting with the amount injected (Jastreboff et al., 2023). - Retatrutide is a single-molecule triple agonist acting on GIP, GLP-1, and glucagon receptors, and its once-weekly design follows directly from that multi-day clearance (Jastreboff et al., 2023). - With a half-life near 6 days, plasma levels take roughly four to five weeks of steady weekly dosing to approach steady state, a standard consequence of drug clearance math. - Any personal dosing question routes to a qualified clinician. This page describes what studies report, not what to take.

What is the retatrutide half life?

The retatrutide half life is approximately 6 days, based on published pharmacokinetic data, and that multi-day value is what supports once-weekly subcutaneous injection (Jastreboff et al., 2023; Coskun et al., 2022).

To state it plainly: the phase 2 obesity trial reported that retatrutide has a half-life of about 6 days, which is why it was given once every week (Jastreboff et al., 2023). The earlier phase 1 work characterized the pharmacokinetic profile as supporting once-weekly dosing, with the drug clearing slowly enough to hold meaningful blood levels across the full seven days between injections (Coskun et al., 2022).

A half-life measured in days, not hours, is the practical fact behind the schedule. Human pharmacokinetic data on retatrutide is still relatively recent, so the roughly 6-day figure should be read as the value reported in early-phase and phase 2 literature rather than a long-settled constant. Even so, the number is published and citable, not withheld.

Why does a 6-day half-life mean once-weekly dosing?

A half-life near 6 days keeps blood levels in a useful range for about seven days, so a single weekly injection covers the interval between doses (Jastreboff et al., 2023).

Half-life is the time for the concentration in the body to fall by half. With a 6-day half-life, only a modest fraction clears over a week, so weekly injections smooth out peaks and troughs instead of letting levels swing sharply. Retatrutide was built as one molecule that engages three receptors, GIP, GLP-1, and glucagon, and the trial used a once-weekly subcutaneous route across all dose arms (Jastreboff et al., 2023).

This mirrors the broader pattern in the incretin class, where longer-acting molecules moved the field from daily to weekly dosing. Tirzepatide, a dual GIP and GLP-1 agonist, is dosed weekly (Jastreboff et al., 2022). Semaglutide is also weekly (Wilding et al., 2021). Retatrutide follows the same weekly cadence for the same pharmacokinetic reason.

How long until retatrutide reaches steady state?

With a half-life of about 6 days, retatrutide approaches steady state after roughly four to five weeks of consistent weekly dosing, because reaching a stable level takes about four to five half-lives (Jastreboff et al., 2023).

Steady state is the point where the amount entering the body each week balances the amount cleared, so the average level stops climbing. This is a general property of drug clearance: each half-life brings the concentration closer to its plateau, and after four to five of them the level is close to stable. For a drug with a roughly 6-day half-life, that arithmetic works out to about a month of weekly dosing before levels flatten.

Two consequences follow from the multi-day clearance. First, the effect of any single dose builds gradually rather than appearing fully at once. Second, after the last dose, a similar multi-week window is needed for levels to fall back toward zero, since clearance runs on the same 6-day clock in reverse.

What does the phase 2 pharmacokinetic profile report?

The trial reported dose-proportional pharmacokinetics and a half-life of approximately 6 days, delivered by once-weekly subcutaneous injection (Jastreboff et al., 2023).

Dose proportional means the half-life did not swing widely with the size of the dose, so the clearance behavior stays consistent across the range studied. These figures describe controlled research, not dosing advice.

How does retatrutide compare to other weekly agents?

All three leading incretin-class agents share a weekly injection schedule, which reflects their multi-day pharmacokinetics.

The through-line is a half-life long enough to hold exposure across a week. Retatrutide adds glucagon-receptor activity to the GIP and GLP-1 mechanism, but its dosing rhythm and multi-day clearance are familiar for the class (Jastreboff et al., 2023). For context on efficacy rather than pharmacokinetics, the highest weekly dose in the phase 2 trial was associated with up to about 24.2 percent weight change at 48 weeks, a trial result and not a recommendation (Jastreboff et al., 2023).

Does retatrutide clear quickly after stopping?

No. Because clearance runs on a roughly 6-day half-life, retatrutide takes several weeks to leave the body after the final dose, and research on this class reports that weight tends to return once drug exposure ends (Aronne et al., 2024).

After tirzepatide was withdrawn in SURMOUNT-4, participants regained weight (Aronne et al., 2024). The STEP 1 extension showed a similar pattern after semaglutide was stopped (Wilding et al., 2022). Part of why is adaptive thermogenesis, the body's tendency to defend a higher weight set point after loss (Rosenbaum and Leibel, 2010). Retatrutide-specific withdrawal data should be read from its own trial reports as they mature, since human data on this compound is still early.